Use of technetium-99m tin colloid for sentinel lymph node identification in non–small cell lung cancer  by Nomori, Hiroaki et al.
General Thoracic
Surgery
Use of technetium-99m tin colloid for sentinel lymph node
identification in non–small cell lung cancer
Hiroaki Nomori, MD,a Hirotoshi Horio, MD,a Tsuguo Naruke, MD,a
Hideki Orikasa, MD,b Kazuto Yamazaki, MD,b and Keiichi Suemasu, MDa
Dr Nomori
See related editorial on page
428.
Background: To test the reliability of sentinel lymph node identification in non–
small cell lung cancer, sentinel nodes were localized with a radioactive colloid in
patients undergoing surgery.
Methods: Forty-six patients with non–small cell lung cancer undergoing curative
resection with mediastinal lymph node dissection were examined. The day before
surgery, technetium-99m (99mTc) tin colloid was injected into the peritumoral region. At
operation, the radioactivity of the lymph nodes was counted with a handheld gamma
counter before (in vivo) and after (ex vivo) dissection. Lymph nodes with an ex vivo
radioactive count more than 10 times the background value were identified as sentinel
nodes. The correlation between the in vivo and ex vivo results was examined.
Results: Lymphoscintigraphy revealed that it took longer than 6 hours for sufficient
99mTc tin colloid to reach the sentinel nodes. Sentinel nodes could be identified in 40
patients (87%). Patients whose sentinel nodes could not be identified had a significantly
lower ratio of forced expiratory volume in 1 second to forced vital capacity than did
those with identifiable sentinel nodes (P  .03). No false-negative sentinel nodes were
detected in 14 patients with N1 or N2 disease (0%). In the hilar lymph node stations, the
lobar lymph nodes were most frequently identified as sentinel nodes (as often as 85%
of the time). Fourteen patients (35%) had sentinel nodes in the mediastinum, the
distribution of which depended on the lobe. In vivo and ex vivo counting showed 88%
concurrence for the identification of sentinel nodes in mediastinal lymph node stations.
Conclusion: The identification of sentinel nodes with 99mTc tin colloid is a reliable
method of establishing the first site of nodal metastasis in non– small cell lung cancer.
Sentinel nodes could be hardly identified in patients with a low ratio of forced expiratory
volume in 1 second to forced vital capacity because of such conditions as chronic
obstructive pulmonary disease. In vivo identification of sentinel nodes in the mediasti-
num could be useful approach to guide mediastinal lymph node sampling or dissection.
Systemic node dissection is a useful procedure for complete localcontrol of non–small cell lung cancer (NSCLC), with subsequentimprovement in survival as well as nodal staging.1-3 To minimize thedamage caused by systemic node dissection, several authors haveexamined the characteristics of lymphatic drainage, as well as theprevalence of lymph node metastasis, with respect to the location of
the primary tumor.4-7 In small lung cancers, which have a relatively low frequency
of mediastinal lymph node metastasis, systemic mediastinal lymph node dissection
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could be reduced by an intraoperative pathologic diagnosis
of sentinel lymph nodes (the first lymph node within the
lymphatic basin reached by lymph draining from the pri-
mary lesion).
Recently, identification of sentinel lymph nodes with a
radioisotope tracer with or without isosulfan blue dye has
been used during surgery for melanoma, breast cancer, and
gastrointestinal cancers, with an accuracy greater than
80%.8-10 In lung cancer surgery, Little and colleagues11
demonstrated the identification rate of sentinel lymph nodes
in fewer than 50% of patients with isosulfan blue dye,
because intrathoracic lymph nodes were usually black,
which made the blue dye method inaccurate. Recently
Liptay and associates12 used a technetium Tc 99m sulfur
colloid and reported that the identification rate for sentinel
lymph nodes was 82% and the accuracy was 95%. In this
study, sentinel lymph nodes were identified with technetium
Tc 99m tin colloid in patients with NSCLC undergoing
curative resection with mediastinal lymph node dissection.
The accuracy and usefulness of this method for effective
lymph node dissection and sampling were determined.
Material and Methods
Eligibility
The study was approved by the ethical committee of Saiseikai
Central Hospital in July 2000. Informed consent was obtained
from all patients after discussion of the risks and benefits with the
operating surgeons. Eligible patients had lung cancers less than 5
cm in size and were candidates for lobectomy or more resection
with mediastinal lymph node dissection.
Administration of Radioactive Colloid
Under Japanese law, the radioisotope could only be injected in a
radioisotope room. A radioisotope tracer was therefore injected
according to the following procedure: (1) in the computed tomog-
raphy room, the site for radioisotope injection was marked on the
skin and the angle and depth of the needle required to reach the
peritumoral region was determined (Figure 1); (2) the day before
surgery, in the radioisotope room, a 23-gauge needle was intro-
duced from the marked point on the skin to the peritumoral region
according to the angle and depth measured; (3) 6 to 8 mCi of
technetium tin colloid suspended in a volume of 1 to 1.5 mL was
injected with a single shot; and (4) lymphoscintigraphy was per-
formed 5 minutes after the injection and the next morning just
before surgery.
Time Course after Radioisotope Injection
For the first 10 patients, the time course was monitored by lym-
phoscintigraphy to determine the optimal timing for radioisotope
injection before surgery. Lymphoscintigraphy was performed 5
minutes and 1, 6, 9, and 24 hours after the injection.
Counting of Radioactivity
The radioactivity in the lymph nodes was counted before (in vivo)
and after (ex vivo) dissection with a handheld gamma probe
(Navigator; Auto Suture Japan, Tokyo, Japan). The radioactivity
count was recorded for a 20-second period. If there was incomplete
fissure between the lobes, the in vivo radioactivity of the hilar
lymph node stations was counted after dividing the fissure and
exposing the lymph nodes.
Criteria for Sentinel Nodes
The lymph node nomenclature used was similar to the lymph node
map for lung cancer reported previously (Table 1).13 For in vivo
counting, sentinel lymph nodes were identified as any node for
which the count was 10 times the intrathoracic background value.
For ex vivo counting, sentinel lymph nodes were defined as any
node for which the count was 10 times the radioactivity of the
resected lung tissue with the lowest count or the resected subder-
Figure 1. By computed tomographic examination, site of injection of radioactive tracer is marked on skin and angle
and depth of needle to reach peritumoral region are determined. At right bottom, angle and depth are recorded.
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mal tissue. Finally, sentinel lymph nodes identified by ex vivo
counting were determined to be the true sentinel lymph nodes,
because in vivo counting could include radioactivity from the
primary tumor.
Pathologic Examinations
The dissected lymph nodes were examined histologically by using
formalin-fixed and paraffin-embedded sections with hematoxylin
and eosin staining. Sentinel lymph nodes without metastasis were
further examined by using three-step sections and immunohisto-
chemical methods with a monoclonal anti–human cytokeratin
antibody (DAKO Corporation, Carpinteria, Calif).
Correlation Between in Vivo and ex Vivo Counting
To clarify the accuracy of in vivo sentinel lymph node identifica-
tion, the correlations for both hilar and mediastinal lymph node
stations between in vivo and ex vivo results were examined.
Statistical Analysis
The Fisher exact test for nominal variables was used to compare
successful sentinel lymph node identification according to the
patient’s age, sex, ratio of forced expiratory volume in 1 second
(FEV1) to forced vital capacity (FVC), tumor location, and patho-
logic N stage. The other data were analyzed for significance with
the 2-tailed Student t test.
Results
From August 2000 to October 2001, a total of 52 patients
were enrolled consecutively into this study. There were no
complications associated with radioisotope injection neces-
sitating tube drainage, such as bleeding or pneumothorax.
Of the 52 patient, 6 were excluded from the study because
of the following reasons: (1) major pulmonary resection
could not be conducted because of the advanced tumor stage
(n  5) and (2) the tumor was identified as small cell
carcinoma (n  1). Of the remaining 46 patients, sentinel
lymph nodes could be identified in 40 (87%). The charac-
teristics of the 40 patients with identifiable sentinel lymph
nodes and of the 6 patients with no identifiable sentinel
lymph nodes are shown in Table 2. The mean value of
FEV1/FVC was 65.3%  9.2% among the patients with
unidentifiable sentinel lymph nodes, which was signifi-
cantly lower than the 74.5%  9.9% value among the
patients with identifiable sentinel lymph nodes (P  .03).
There were no significant differences between the two
groups in factors other than FEV1/FVC ratio.
Figure 2 shows the time course after radioisotope injec-
tion determined by lymphoscintigraphy. Five minutes after
the injection, some of the radioisotope had leaked into the
tracheobronchus. One hour after the injection, the radioiso-
tope in the tracheobronchus had washed out, but it had not
TABLE 1. Lymph node nomenclature
N2 node N1 node
Station Name Station Name
Superior mediastinal Hilar
1 Highest mediastinal 10 Hilar
2 Paratracheal 11 Interlobar
3 Pretracheal 12 Lobar
4 Tracheobronchial Intrapulmonary
Aortic 13 Segmental
5 Botallo 14 Subsegmental
6 Para-aortic
Inferior mediastinal
7 Subcarinal
8 Paraesophageal
9 Pulmonary ligament
TABLE 2. Patient characteristics
Sentinel lymph nodes
Identified Not identified
Age (y)
Mean  SD 62 11 65 9
Range 38–82 56–78
Sex (No.)
Male 36 6
Female 4 0
FEV1/FVC ratio (%)
Mean  SD 74.5 9.9 65.39.2
Range 51–90 55–76
Tumor location (No.)
Right upper lobe 12 2
Right middle lobe 4 1
Right lower lobe 8 1
Left upper lobe 10 1
Left lower lobe 6 1
Histologic type (No.)
Adenocarcinoma 27 4
Squamous cell carcinoma 12 2
Adenosquamous carcinoma 1 0
Operative procedure (No.)
Lobectomy 38 6
Pneumonectomy 2 0
pTNM (No.)
N0
T1 N0 M0 16 3
T2 N0 M0 8 1
T4 N0 M0 2 0
N1
T1 N1 M0 4 0
T2 N1 M0 1 1
N2
T1 N2 M0 2 0
T2 N2 M0 5 0
T3 N2 M0 1 0
T4 N2 M0 1 1
Total (No.) 40 6
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been taken up by the lymph nodes. More than 6 hours after
the injection, sufficient radioisotope had been taken up by
the lymph nodes, and its detection did not change until 24
hours after the injection.
The mean number of sentinel lymph nodes identified was
2.0 0.7 (range 1-4) stations per patient. Table 3 shows the
sentinel lymph nodes identified in the hilar lymph node
stations. The hilar lymph node (No. 10) was identified as a
sentinel lymph node in 7 patients (18%), the interlobar node
(No. 11) was identified in 12 (30%), the lobar node (No. 12)
was identified in 34 (85%), and the segmental node (No. 13)
was identified in 13 (33%). The lobar lymph nodes were
identified as sentinel lymph nodes significantly more fre-
quently than were the other lymph node stations (P 1.6
1.9  109).
In the mediastinal lymph node stations, the sentinel
lymph nodes were identified in 14 (35%) of the 40 patients.
Thirteen of the 14 patients had sentinel lymph nodes in both
the mediastinal and hilar lymph node stations. The remain-
ing patient had sentinel lymph nodes only in the Botallo
lymph node, with primary tumor located in the left upper
lobe. The distribution of mediastinal sentinel lymph nodes
is shown in Table 4. Five (42%) of 12 patients with primary
tumors in the right upper lobe had sentinel lymph nodes at
the pretracheal (No. 3) or tracheobronchial (No. 4) lymph
nodes. Two (25%) of 8 patients with primary tumors in the
right lower lobe had sentinel lymph nodes in both the
tracheobronchial (No. 4) and subcarinal (No. 7) lymph
nodes. Five (50%) of 10 patients with primary tumors in the
left upper lobe had sentinel lymph nodes at the Botallo (No.
5) lymph node. Two of six (33%) patients with primary
tumors in the left lower lobe had sentinel lymph nodes in the
subcarinal (No. 7) lymph nodes.
The false-negative rate for sentinel lymph node identifi-
cation was assessed by the presence of metastatic lymph
nodes not identified as sentinel lymph nodes with the la-
beled sentinel lymph nodes histologically appearing unin-
volved. As a result, no false-negative sentinel lymph nodes
were detected in any of the 14 patients with N1 or N2
disease (0%).
Step sections and immunohistochemical examination re-
vealed micrometastasis in 1 of the 63 sentinel lymph nodes
(2%), without metastasis in the routine hematoxylin and
eosin–stained sections. This result did not change the tumor
stage in that patient.
Figure 2. Time course examined by lymphoscintigraphy shows lymph node clearly demonstrated 6 hours after
injection of radioactive technetium tin colloid.
TABLE 3. Sentinel lymph node mapping in the hilar lymph
node stations
Station
Sentinel nodes
No. %
10 Hilar 7/40 18
11 Interlobar 12/40 30
12 Lobar 34/40 85
13 Segmental 13/40 33
TABLE 4. Tumor locations at which sentinel nodes were
identified in the mediastinal lymph node stations
Tumor location Station of mediastinal sentinel node No. %
Right upper lobe Pretracheal or tracheobronchial 5/12 42
Right lower lobe Tracheobronchial and subcarinal 2/8 25
Left upper lobe Botallo 5/10 50
Left lower lobe subcarinal 2/6 33
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Whereas the relationship between in vivo and ex vivo
results for the hilar lymph node stations showed concur-
rence in 20 patients (50%) for the hilar lymph nodal sta-
tions, 35 patients (88%) showed concurrence for the medi-
astinal lymph node stations; this difference was statistically
significant (P  .0003). Of the 5 patients who did not show
a correlation in the mediastinal lymph node stations, 1
appeared to have an additional sentinel lymph node on ex
vivo counting, whereas the sentinel lymph nodes identified
by in vivo counting in the other 4 were judged not to be
sentinel lymph nodes by ex vivo counting.
Discussion
The procedure described in this study identified sentinel
lymph nodes in 40 of 46 patients (87%) with NSCLC, a rate
that is comparable to those described in previous reports for
other organs.8-10 Sentinel lymph nodes were difficult to
identify in patients with a low FEV1/FVC ratio, such as
those with chronic obstructive pulmonary disease. In breast
cancer, it has been reported that the sentinel lymph node
identification rate is significantly lower in older than in
younger patients, probably because breast tissue becomes
progressively replaced by fat and its lymphatic vessel den-
sity decreases in older patients.8 We consider that lung
tissue in patients with chronic obstructive pulmonary dis-
ease could also have a lower density of lymphatic vessels or
low lymphatic flow than normal lung tissue, resulting in the
lower sentinel lymph node identification rate.
Liptay and associates12 identified sentinel lymph nodes
in lung cancer after intraoperative injection of 99mTc sulfur
colloid with a particle size of approximately 40 nm diame-
ter. The particles of 99mTc tin colloid, on the other hand, are
much larger than those of a 99mTc sulfur colloid, about 1000
nm in diameter, and should therefore take longer to reach
the sentinel lymph nodes than the 99mTc sulfur colloid. As
shown in Figure 2, it took several hours for sufficient 99mTc
tin colloid to reach the sentinel lymph nodes. Although the
optimum particle size for the radioisotope tracer for sentinel
lymph node identification in lung cancer patients has not
been clarified, we believe that 99mTc tin colloid would be
more suitable than 99mTc sulfur colloid for the following
reasons. First, 99mTc sulfur colloid can reach the sentinel
lymph nodes rapidly, because of its small particle size, but
could pass through the true sentinel lymph nodes and flow
further up the chain of nodes, resulting in false-negative
results. Actually, it has been reported that the hottest node
with 99mTc sulfur colloid is not always the sentinel lymph
node in patients with melanoma.14 On the other hand, a
99mTc tin colloid, because of its large particle size, could be
lodged within the sentinel lymph nodes for a longer period
than a 99mTc sulfur colloid, which could make the false
negative rate lower. Second, unlike in other organs, radio-
isotope injected into the lung frequently leaks into the
tracheobronchus, as shown in Figure 2. This could make in
vivo counting unreliable immediately after the injection. A
99mTc sulfur colloid procedure, because of its intraoperative
injection, could result in the radioisotope tracer leaking into
the tracheobronchus and make the radioactivity of lymph
nodes around the tracheobronchus higher than the true
value. On the other hand, because 99mTc tin colloid has to be
injected a few hours before surgery, the material leaked into
the tracheobronchus has been already washed out at surgery,
resulting in more reliable in vivo counting. Finally, intra-
operative injection of 99mTc sulfur colloid might not reveal
the natural lymphatic flow because of the thoracotomy itself
and intraoperative manipulation of lung. However, a com-
parison of our results with those of Liptay and associates12
with 99mTc sulfur colloid revealed similar results: (1) the
identification rate for sentinel lymph nodes was 82% by the
method of Liptay and associates,12 compared with 87% by
our method; (2) mediastinal sentinel lymph nodes were
found in 22% of patients by Liptay and associates12 and in
35% in this study; and (3) false-negative results were ob-
served in 5% of patients by Liptay and associates12 and in
none of our patients.
In the hilar lymph node stations, sentinel lymph nodes
were identified most frequently in the lobar lymph node
(No. 12). The reason for the lower frequency of sentinel
lymph nodes in the interlobar (No. 11) and hilar (No. 10)
lymph nodes can be explained by the fact that these nodes
are located further away from the primary tumor than are
the lobar (No. 12) nodes. However, although the segmental
(No. 13) lymph nodes were located nearer to the primary
tumor than the lobar (No. 12) nodes, the former were
identified as sentinel lymph nodes less frequently than the
latter. This observation is similar to those in previous re-
ports, which demonstrated that lymph node metastases of
lung cancer were more frequent in the lobar (No. 12) lymph
nodes than in the segmental (No. 13) nodes.4,15 We consider
that this might be due to the following reasons: (1) some of
the lymphatic flow passes through lymphatic vessels of the
visceral pleura and goes to the lobar lymph nodes but not
through the segmental nodes and (2) some of the lymphatic
flow within the lung tissue goes directly to the lobar lymph
nodes without passing through the segmental nodes.
Skip metastasis to the mediastinal lymph nodes has
been reported to occur in 20% to 40% of patients with
NSCLC,4-6,15 which could be because some lymphatic
flow from the lung goes directly to the mediastinum through
the pleura and not to the hilar lymph node stations.16 Our
study showed that sentinel lymph nodes were identified in
35% of mediastinal lymph nodes, and that the lymphatic
route to each mediastinal lymph node station was lobe
specific; the lymphatic flow from the right upper lobe pro-
ceeds to the pretracheal or tracheobronchial lymph nodes,
the left upper lobe to the Botallo node, and the lower lobe
to the subcarinal node. This result is supported by previous
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reports, which showed a similar distribution of prevalence
of mediastinal lymph node metastases from each lobe.4-6,15
One of the potential benefits of sentinel lymph node
identification is that pathologists can focus on fewer lymph
nodes when identifying micrometastases by immunohisto-
chemical assay or polymerase chain reaction. Izbicki and
coworkers17 used immunohistochemical methods and re-
ported that 27% of patients with N0 and 45% with N1
staged from frozen tissue sections had micrometastases in
the mediastinal lymph node stations, resulting in upstaging.
However, both step sections and immunohistochemical as-
say for sentinel lymph nodes in this study showed micro-
metastases in only 1 of the 40 patients (3%). This could be
because we examined formalin-fixed and paraffin-embed-
ded tissue sections but not frozen sections alone.
There have been few reports comparing sentinel lymph
node identification by in vivo and ex vivo counting, includ-
ing other organ tumors. Although ex vivo counting is more
accurate than in vivo counting, it is not practical for sentinel
lymph node navigation surgery because it is only available
after dissection. To be of practical use for sentinel lymph
node navigation surgery, the in vivo counting data have to
be accurate. We therefore examined the correlation between
in vivo and ex vivo counting for both hilar and mediastinal
lymph node stations. Our results indicated that whereas the
hilar lymph node stations showed concurrence between the
in vivo and ex vivo results in only 50% of patients, the
mediastinal nodes showed concurrence in 88%. This could
be because the mediastinal lymph node stations were less
affected by “shine through” from the hot primary. Of the 4
patients with inconsistency between in vivo and ex vivo
results for the mediastinal lymph node stations, only 1
showed an additional sentinel lymph node by ex vivo count-
ing. That is to say, the rate of overlooking sentinel lymph
nodes by in vivo counting of mediastinal lymph node sta-
tions was only 3% (1 of 40 patients). We therefore believe
that sentinel lymph node identification by in vivo counting
of mediastinal lymph node stations could be a useful ap-
proach to guide mediastinal lymph node sampling or dis-
section. We also recommend 99mTc tin colloid rather than
99mTc sulfur colloid for sentinel lymph node identification
in lung cancer surgery, because in vivo counting by the
former procedure could be less affected by the radioisotope
leaked into tracheobronchus, as discussed previously.
How can sentinel lymph node biopsy change surgical
procedures for NSCLC? First, it should be stated that sen-
tinel lymph node identification is not practical for lung
wedge resection, because the radioactivity of hilar lymph
node stations cannot be determined by the wedge resection
procedure. To evaluate the hilar lymph nodal stations, seg-
mentectomy or greater resection is necessary. Second, we
consider that sentinel lymph node biopsy could reduce
systemic mediastinal lymph node dissection. For example,
if all the dissected hilar lymph node stations and the medi-
astinal sentinel lymph nodes identified by in vivo counting
showed no metastasis after lobectomy, mediastinal lymph
node dissection would not be necessary. Third, sentinel
lymph node identification could be useful as an indication
for segmentectomy; after segmentectomy, if all the dis-
sected hilar lymph node stations and mediastinal sentinel
lymph nodes identified by in vivo counting revealed no
metastasis, segmentectomy could be enough for curative
resection, especially for small lung cancers. Okada and
coworkers18 reported that segmentectomy with mediastinal
lymph node dissection for lung cancers less than 2 cm in
size with clinical N0 stage carried a 5-year survival similar
to that seen with lobectomy. Whereas their procedure re-
quired intraoperative pathologic diagnosis for all the dis-
sected lymph nodes, including the mediastinal nodes, our
procedure could reduce the number of lymph nodes exam-
ined during surgery.
Although sentinel lymph node biopsy was developed for
breast cancer and melanoma, recent articles have demon-
strated that this procedure has no advantage relative to
elective lymph node dissection or sampling in patients with
these diseases.19,20 We therefore consider that further exam-
ination, including multicenter trials, is necessary to deter-
mine the role of sentinel lymph node identification in
NSCLC.
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